Human immunoglobulin G
- Generic Name
- Human immunoglobulin G
- Brand Names
- Asceniv, Bivigam, Cuvitru, Flebogamma, Gamastan, Gammagard, Gammaked, Gammaplex, Gamunex, Hizentra, Hyqvia 5 G / 50 Ml Kit, Igivnex, Kiovig, Octagam, Panzyga, Privigen, Xembify, HyQvia, Flebogamma DIF (previously Flebogammadif)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-58-5
- Unique Ingredient Identifier
- 66Y330CJHS
- Background
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human ...
- Indication
Human immunoglobulin G is indicated for the following conditions:
- Associated Conditions
- Acute Idiopathic Thrombocytopenic Purpura, Bacterial Infections, Chronic Idiopathic Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Coronary Artery Aneurysm, Dermatomyositis (DM), Hepatitis A, Measles, Multifocal Motor Neuropathy (MMN), Primary humoral immunodeficiency, Rubella, Secondary humoral immunodeficiency, Varicella
- Associated Therapies
- Maintenance therapy
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Chafic Karam
- Target Recruit Count
- 30
- Registration Number
- NCT05701189
- Locations
- 🇺🇸
Hospital of University of Pennsylvania, Philadelphia, Pennsylvania, United States
Therapies for Down Syndrome Regression Disorder
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 66
- Registration Number
- NCT05662228
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 386
- Registration Number
- NCT05645107
- Locations
- 🇺🇸
GC2202 Study Site 103, Saint Petersburg, Florida, United States
🇺🇸GC2202 Study Site 109, Greenville, North Carolina, United States
🇧🇬GC2202 Study Site 203, Plovdiv, Bulgaria
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
- Conditions
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 5
- Registration Number
- NCT05494593
- Locations
- 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Phoenix Childrens Hospital, Phoenix, Arizona, United States
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT05156710
- Locations
- 🇺🇸
Harvard Medical School - Massachusetts General Hospital (MGH) - Medical Practice Evaluation Center (MPEC)- Site Number : 8400007, Boston, Massachusetts, United States
🇺🇸Cedars-Sinai Medical Center- Site Number : 8400100, Los Angeles, California, United States
🇺🇸University of California Los Angeles Medical Center- Site Number : 8400103, Los Angeles, California, United States
Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 30
- Registration Number
- NCT04929236
- Locations
- 🇺🇸
Octapharma Research Site, Philadelphia, Pennsylvania, United States
Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
- Conditions
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 71
- Registration Number
- NCT04508530
- Locations
- 🇸🇪
Octapharma Research Site, Stockholm, Sweden
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 247
- Registration Number
- NCT04502030
- Locations
- 🇹🇷
Octapharma Research Site, Melikgazi/Kayseri, Turkey
Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- George Sakoulas, MD
- Target Recruit Count
- 34
- Registration Number
- NCT04411667
- Locations
- 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Centenario Hospital Miguel Hidalgo
- Target Recruit Count
- 196
- Registration Number
- NCT04381858
- Locations
- 🇲🇽
Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.